Taysha Gene Therapies, Inc. - Common Stock (TSHA)
Frequently Asked Questions About Taysha Gene Therapies, Inc. - Common Stock (TSHA)
How can investors learn more about Taysha?
Investors can learn more about Taysha Gene Therapies through its official website, by reviewing its filings with the Securities and Exchange Commission (SEC), and through financial news outlets that cover biotechnology companies.
How does Taysha contribute to the scientific community?
Taysha contributes to the scientific community by publishing research findings, participating in scientific conferences, and collaborating with academic institutions to advance knowledge in the field of gene therapy.
How does Taysha ensure the quality of its therapies?
Taysha adheres to strict regulatory guidelines and conducts comprehensive quality control and assurance practices to ensure the safety and efficacy of its gene therapies.
How does Taysha plan to use gene therapy?
Taysha aims to use gene therapy to replace or repair faulty genes responsible for disorders, potentially offering curative treatments that significantly improve the quality of life for affected patients.
Is Taysha Gene Therapies publicly traded?
Yes, Taysha Gene Therapies is a publicly traded company listed on the Nasdaq stock exchange under the ticker symbol TSHA, allowing investors to buy and sell shares of the company.
What are some challenges Taysha faces?
Taysha faces challenges typical of biotech firms, including the high financial costs of research, regulatory hurdles for product approvals, and competition from other gene therapy companies in the industry.
What are Taysha's funding strategies?
Taysha’s funding strategies include raising capital through public offerings, strategic partnerships, and venture capital investments to support its research, development, and operational needs.
What are Taysha's long-term goals?
Taysha's long-term goals include expanding its gene therapy pipeline, achieving therapeutic breakthroughs for rare diseases, and establishing itself as a leader in the field of genetic medicine.
What are the expected outcomes of Taysha’s gene therapies?
The expected outcomes of Taysha’s gene therapies include improvements in clinical symptoms, functional abilities, and overall quality of life for patients suffering from genetic disorders.
What does Taysha Gene Therapies, Inc. do?
Taysha Gene Therapies, Inc. is a biotechnology company focused on developing and delivering innovative gene therapies to treat monogenic diseases, primarily those affecting the central nervous system, such as various forms of neurodegeneration and related disorders.
What is Taysha's lead product candidate?
Taysha’s lead product candidate is TSHA-101, a gene therapy aimed at treating Rett syndrome, a severe neurodevelopmental disorder predominantly affecting females.
What is the mission of Taysha Gene Therapies?
Taysha’s mission is to provide transformative therapies for patients with life-threatening genetic conditions, driven by a commitment to innovation, patient care, and advancing the field of gene therapy.
What is the pipeline status for Taysha’s products?
Taysha has a robust pipeline of product candidates in various stages of preclinical and clinical development, focused on rare and underserved genetic conditions, with ongoing evaluations for safety and efficacy.
What is the stock symbol for Taysha Gene Therapies?
Taysha Gene Therapies trades under the stock symbol TSHA on the Nasdaq stock exchange, indicating its public presence and investment opportunities.
What partnerships does Taysha have?
Taysha has established multiple collaborations with leading academic and research institutions to enhance its research capabilities and accelerate the development of its gene therapies.
What types of therapies does Taysha develop?
Taysha specializes in developing gene therapies based on adeno-associated virus (AAV) vectors to address genetic disorders, particularly those that affect the brain and spinal cord.
When was Taysha Gene Therapies founded?
Taysha Gene Therapies was founded in 2020, and it has since been dedicated to advancing genetic medicine through its cutting-edge research and development in gene therapy technologies.
Where is Taysha Gene Therapies located?
The company is headquartered in Dallas, Texas, which provides access to a vibrant biotechnology ecosystem, collaboration opportunities, and a skilled talent pool.
Who are the founders of Taysha Gene Therapies?
The company was co-founded by Dr. A. J. T. (Tyler) Wilson, who also serves as the CEO, alongside a team of experienced professionals in the fields of medicine and biotechnology.
Who is on Taysha's management team?
Taysha's management team comprises seasoned professionals from the biotechnology and pharmaceutical industries, including experts with backgrounds in research, clinical development, and corporate management.
What is the current price of Taysha Gene Therapies, Inc. - Common Stock?
The current price of Taysha Gene Therapies, Inc. - Common Stock is 1.320
When was Taysha Gene Therapies, Inc. - Common Stock last traded?
The last trade of Taysha Gene Therapies, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Taysha Gene Therapies, Inc. - Common Stock?
The market capitalization of Taysha Gene Therapies, Inc. - Common Stock is 85.09M
How many shares of Taysha Gene Therapies, Inc. - Common Stock are outstanding?
Taysha Gene Therapies, Inc. - Common Stock has 64.47M shares outstanding.